Skip to content
Screener

BioCryst Pharmaceuticals BCRX Royalty Financing Liabilities

Royalty Financing Liabilities at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$0
uniQure logo
uniQureQURE
$10.21M-16.8%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$2.49M-10.7%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$207.21M+1.7%
Regenxbio logo
RegenxbioRGNX
$26.77M-33.6%
Regenxbio logo
RegenxbioRGNX
$154.75M+0.7%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.38B+31.6%
Enterprise value$2.63B+33.4%
P/S2.5×-0.7×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:RoyaltyFinancingLiabilities.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300
Balance as of December 31, 2025$$169,559$$172,671$$123,458$$465,688
Non-cash interest expense on royalty financing obligations10,1113,18313,294
Royalty revenues payable(14,132)(1,220)(16,132)(31,484)
Balance as of March 31, 2026$$165,538$$171,451$$110,509$$447,498
Non-cash interest expense on royalty financing obligations10,1592,87713,036
Royalty revenues paid and payable(15,148)(1,309)(17,288)(33,745)
Balance as of June 30, 2026$$160,549$$170,142$$96,098$$426,789
Effective interest rate24.010.3

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's royalty financing liabilities?
BioCryst Pharmaceuticals (BCRX) reported royalty financing liabilities of $426.79M in Q2 2026.
How has BioCryst Pharmaceuticals's royalty financing liabilities changed year-over-year?
BioCryst Pharmaceuticals's royalty financing liabilities decreased by 11.7% year-over-year, from $483.58M to $426.79M.
What is the long-term trend for BioCryst Pharmaceuticals's royalty financing liabilities?
Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's royalty financing liabilities has grown at a -6.4% compound annual growth rate (CAGR), from $531.6M to $465.69M.
What does royalty financing liabilities mean?
Royalty Financing Liabilities as reported by BioCryst Pharmaceuticals Inc.

Ask your AI about BioCryst Pharmaceuticals's royalty financing liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude